Cantor Fitzgerald Issues Negative Outlook for STOK Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Stoke Therapeutics in a note issued to investors on Wednesday, November 5th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn $0.03 per share for the year, down from their previous estimate of $0.27. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Cantor Fitzgerald also issued estimates for Stoke Therapeutics’ FY2026 earnings at ($3.49) EPS.

Several other equities research analysts have also recently weighed in on the stock. Wedbush upped their price target on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research report on Wednesday. Canaccord Genuity Group upped their target price on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday. JPMorgan Chase & Co. increased their target price on Stoke Therapeutics from $15.00 to $25.00 and gave the company a “neutral” rating in a research report on Monday, November 3rd. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research report on Friday, July 18th. They issued a “buy” rating and a $30.00 price target for the company. Finally, Needham & Company LLC upped their price objective on Stoke Therapeutics from $22.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, October 10th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $22.86 on Friday. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of 34.12 and a beta of 1.32. The firm’s 50-day moving average is $26.47 and its two-hundred day moving average is $17.17. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The firm had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%.

Insiders Place Their Bets

In related news, Director Edward M. Md Kaye sold 45,996 shares of the company’s stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $20.13, for a total value of $925,899.48. Following the transaction, the director directly owned 91,585 shares of the company’s stock, valued at $1,843,606.05. This represents a 33.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Barry Ticho sold 5,931 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $25.72, for a total value of $152,545.32. Following the completion of the transaction, the insider owned 7,195 shares of the company’s stock, valued at $185,055.40. This trade represents a 45.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 186,607 shares of company stock valued at $4,224,210. Insiders own 9.50% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several large investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP increased its holdings in shares of Stoke Therapeutics by 22.5% in the third quarter. GSA Capital Partners LLP now owns 47,583 shares of the company’s stock valued at $1,118,000 after purchasing an additional 8,744 shares during the period. Vanguard Group Inc. increased its holdings in Stoke Therapeutics by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock worth $74,351,000 after buying an additional 217,616 shares during the period. Rhumbline Advisers lifted its stake in Stoke Therapeutics by 2.8% during the 3rd quarter. Rhumbline Advisers now owns 68,304 shares of the company’s stock valued at $1,605,000 after acquiring an additional 1,885 shares during the period. Alps Advisors Inc. boosted its holdings in shares of Stoke Therapeutics by 51.8% in the 3rd quarter. Alps Advisors Inc. now owns 44,664 shares of the company’s stock valued at $1,050,000 after acquiring an additional 15,234 shares during the last quarter. Finally, Penserra Capital Management LLC acquired a new stake in shares of Stoke Therapeutics in the third quarter worth $3,539,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.